Citadel Advisors’s Coya Therapeutics COYA Stock Holding History

Citadel Advisors’s Portfolio COYA Stock Details COYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$66.4K	Sell	16,859 -3,224	-16%	-$15.1K	﹤0.01%	12280
2025 Q4	$116K	Sell	20,083 -45,157	-69%	-$275K	﹤0.01%	11518
2025 Q3	$372K	Buy	65,240 +22,120	+51%	+$135K	﹤0.01%	9844
2025 Q2	$248K	Buy	43,120 +9,176	+27%	+$53.1K	﹤0.01%	10233
2025 Q1	$220K	Buy	+33,944	New	+$215K	﹤0.01%	10271
2024 Q1	–	Sell	-16,592	Closed	-$123K	–	14654
2023 Q4	$123K	Buy	+16,592	New	+$92K	﹤0.01%	10672
2023 Q3	–	Sell	-10,537	Closed	-$42.9K	–	14376
2023 Q2	$42.9K	Buy	+10,537	New	+$48.9K	﹤0.01%	11989

Other funds holding COYA

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

PMG

Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's COYA Position: Q1 2026 in Review

Citadel Advisors reduced its Coya Therapeutics (COYA) stake by 16% in Q1 2026, selling an estimated $15.1K and leaving 16,859 shares worth $66.4K. The position accounts for ﹤0.01% of the portfolio, ranked #12280.

Citadel Advisors first reported a position in COYA in Q2 2023 and has held it in 7 quarters since. The position peaked at $372K in Q3 2025. 56 funds tracked by Wall St. Rank hold COYA as of Q1 2026.

Citadel Advisors held 16,859 shares of Coya Therapeutics worth $66.4K as of Q1 2026.
Citadel Advisors sold 3,224 Coya Therapeutics shares in Q1 2026, an estimated $15.1K.
Coya Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12280 holding.
Citadel Advisors first reported a position in Coya Therapeutics in Q2 2023 and has held it in 7 quarters since.
Citadel Advisors's Coya Therapeutics position peaked at $372K in Q3 2025.
56 funds tracked by Wall St. Rank held Coya Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.